Morgan Stanley

13F Holdings History for Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA)

Symbol: TSHA on Nasdaq
Investment type: Equity / Common Stock, $0.00001 par value per share
Latest Disclosed Ownership: 16.9M shares
Security Ownership: 6.7%

Shares, Excluding Options vs Price

Value, Excluding Options

Morgan Stanley ownership in Taysha Gene Therapies, Inc. Common Stock, $0.00001 par value per share (TSHA)

2025-08-06 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 16.9M shares of Taysha Gene Therapies, Inc. Common Stock, $0.00001 par value per share (TSHA). This represents 6.7% percent ownership of the company. In their previous filing dated 2025-02-05, MORGAN STANLEY had reported owning 17.6M shares, indicating a decrease of -4.37% percent.

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filed at
Morgan Stanley	6.7%	-21.1%	$39.1M	16.9M	-770,620	-4.37%	$2.32	13G/A	6/30/2025	6 Aug 2025 14:13:20
Morgan Stanley	8.6%		$22M	17.6M			$1.25	13G	12/31/2024	5 Feb 2025 10:43:37

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
6/30/2025	0%	+0%	$39M	16.9M	+18,708	+0.11%	$2.31	Q2 2025
3/31/2025	0%	0%	$23.4M	16.8M	-793,992		$1.39	Q1 2025
12/31/2024	0%	+0%	$30.5M	17.6M	+9,976,373	+100%	$1.73	Q4 2024
9/30/2024	0%	+0%	$15.4M	7.66M	+186,596		$2.01	Q3 2024
6/30/2024	0%	+0%	$16.7M	7.48M	+2,308,507		$2.24	Q2 2024
3/31/2024	0%		$14.8M	5.17M			$2.87	Q1 2024
12/31/2023	0%		$383K	217K			$1.77	Q4 2023
9/30/2023	0%	+0%	$544K	172K	+40,761	+31%	$3.16	Q3 2023
6/30/2023	0%	+0%	$86.8K	131K	+43,495	+49.5%	$0.66	Q2 2023
3/31/2023	0%	+0%	$70K	87.8K	+64,206	+272%	$0.80	Q1 2023
12/31/2022	0%		$53.4K	23.6K	-1,334	-5.35%	$2.26	Q4 2022
9/30/2022	0%	0%	$48K	24.9K	-46,632	-65.2%	$1.92	Q3 2022
6/30/2022	0%	0%	$265K	71.6K	-104,182	-59.3%	$3.70^*	Q2 2022
3/31/2022	0%	+0%	$1.15M	176K	+33,445	+23.5%	$6.53^*	Q1 2022
12/31/2021	0%	+0%	$1.66M	142K	+17,251	+13.8%	$11.65	Q4 2021
9/30/2021	0%		$2.33M	125K			$18.62	Q3 2021
6/30/2021	0%	+0%	$766K	36.1K	+13,145	+57.2%	$21.22	Q2 2021
3/31/2021	0%	0%	$466K	23K	-8,377	-26.7%	$20.30	Q1 2021
12/31/2020	0%	+0%	$832K	31.3K	+31,338	NEW	$26.55	Q4 2020

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.